Phenotype of patients with late diagnosis of 22q11 deletion: a review and retrospective study.
22q11 deletion syndrome
DiGeorge syndrome
hypoparathyroidism
intellectual disability
late diagnosis
Journal
Internal medicine journal
ISSN: 1445-5994
Titre abrégé: Intern Med J
Pays: Australia
ID NLM: 101092952
Informations de publication
Date de publication:
19 Oct 2024
19 Oct 2024
Historique:
received:
27
02
2024
accepted:
17
09
2024
medline:
19
10
2024
pubmed:
19
10
2024
entrez:
19
10
2024
Statut:
aheadofprint
Résumé
Chromosome 22q11.2 deletion syndrome (22q11DS) is the most common microdeletion syndrome, typically presenting in neonates with congenital cardiac anomalies, hypocalcaemia and thymic hypoplasia. Some patients are diagnosed later in adolescence and adulthood, with less known about the clinical phenotype of these patients. To summarise key clinical features in cases of 22q11DS diagnosed during adolescence and adulthood. This is a retrospective cohort study of 22q11DS patients diagnosed after 13 years of age over 2010-2021, with a literature review of published cases highlighting other late diagnoses. The study was performed in a large multicentre tertiary health network in Melbourne, Australia. Patients diagnosed with 22q11DS after the age of 13 years were included in the study. Main outcome measures were key clinical features in cases of late diagnosis of 22q11DS. A literature search yielded 53 published case reports and one cohort study for review (62 subjects). Additionally, 10 cases of late diagnosis of 22q11DS were identified through a retrospective electronic medical chart review. Findings suggest that intellectual disability and learning difficulties, hypocalcaemia with hypoparathyroidism and facial dysmorphism remain key features in patients with a late diagnosis of 22q11DS, with hypocalcaemia being the most common presentation leading to diagnosis. Patients diagnosed in adulthood may lack classical clinical features of congenital cardiac anomalies and thymic hypoplasia. Immunological consequences of 22q11DS are also an important late-onset consideration. Atypical features may include basal ganglia calcification. Chromosome 22q11DS has diverse clinical features and a highly variable phenotype, likely contributing to underdiagnosis and later diagnoses.
Sections du résumé
BACKGROUND
BACKGROUND
Chromosome 22q11.2 deletion syndrome (22q11DS) is the most common microdeletion syndrome, typically presenting in neonates with congenital cardiac anomalies, hypocalcaemia and thymic hypoplasia. Some patients are diagnosed later in adolescence and adulthood, with less known about the clinical phenotype of these patients.
AIM
OBJECTIVE
To summarise key clinical features in cases of 22q11DS diagnosed during adolescence and adulthood.
METHODS
METHODS
This is a retrospective cohort study of 22q11DS patients diagnosed after 13 years of age over 2010-2021, with a literature review of published cases highlighting other late diagnoses. The study was performed in a large multicentre tertiary health network in Melbourne, Australia. Patients diagnosed with 22q11DS after the age of 13 years were included in the study. Main outcome measures were key clinical features in cases of late diagnosis of 22q11DS.
RESULTS
RESULTS
A literature search yielded 53 published case reports and one cohort study for review (62 subjects). Additionally, 10 cases of late diagnosis of 22q11DS were identified through a retrospective electronic medical chart review. Findings suggest that intellectual disability and learning difficulties, hypocalcaemia with hypoparathyroidism and facial dysmorphism remain key features in patients with a late diagnosis of 22q11DS, with hypocalcaemia being the most common presentation leading to diagnosis. Patients diagnosed in adulthood may lack classical clinical features of congenital cardiac anomalies and thymic hypoplasia. Immunological consequences of 22q11DS are also an important late-onset consideration. Atypical features may include basal ganglia calcification.
CONCLUSIONS
CONCLUSIONS
Chromosome 22q11DS has diverse clinical features and a highly variable phenotype, likely contributing to underdiagnosis and later diagnoses.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Author(s). Internal Medicine Journal published by John Wiley & Sons Australia, Ltd on behalf of Royal Australasian College of Physicians.
Références
Kuo CY, Signer R, Saitta SC. Immune and genetic features of the chromosome 22q11. 2 deletion (DiGeorge syndrome). Curr Allergy Asthma Rep 2018; 18: 1–7.
Lischner HW. DiGeorge syndrome(s). J Pediatr 1972; 81: 1042–1044.
McDonald‐McGinn DM, Sullivan KE. Chromosome 22q11. 2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome). Medicine 2011; 90: 1–18.
Campbell IM, Sheppard SE, Crowley TB, McGinn DE, Bailey A, McGinn MJ et al. What is new with 22q? An update from the 22q and You Center at the Children's Hospital of Philadelphia. Am J Med Genet A 2018; 176: 2058–2069.
Óskarsdóttir S, Boot E, Crowley TB, Loo JCY, Arganbright JM, Armando M et al. Updated clinical practice recommendations for managing children with 22q11. 2 deletion syndrome. Genet Med Open 2023; 25: 100338.
Cohen E, Chow EW, Weksberg R, Bassett AS. Phenotype of adults with the 22q11 deletion syndrome: a review. Am J Med Genet 1999; 86: 359–365.
Cancrini C, Puliafito P, Digilio MC, Soresina A, Martino S, Rondelli R et al. Clinical features and follow‐up in patients with 22q11.2 deletion syndrome. J Pediatr 2014; 164: 1475–1480.
Vervoort L, Vermeesch JR. The 22q11. 2 low copy repeats. Gene 2022; 13: 2101.
ClinGen. Curations of recurrent CNVs [cited 2024 Jul 27]. Available from URL: https://search.clinicalgenome.org/kb/gene-dosage/cnv?page=1&size=25&search=
Riggs ER, Andersen EF, Cherry AM, Kantarci S, Kearney H, Patel A et al. Technical Standards for the Interpretation and Reporting of Constitutional Copy‐Number Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics (ACMG) and the Clinical Genome. Genet Med 2020; 22: 245–247.
Abrantes C, Brigas D, Casimiro HJ, Madeira M. Hypocalcaemia in an adult: the importance of not overlooking the cause. BMJ Case Rep 2018; 2018: bcr2017224108.
Aljabri K, Bebb R. DiGeorge's syndrome presenting as hypocalcemia in an adult. Ann Saudi Med 2005; 25: 173–174.
Batra N, Kant R, Mandal K, Joshi K. A rare etiology of Hypocalcemic seizures in adulthood: clues to diagnosis from facial dysmorphism. Neurol India 2021; 69: 161–163.
Cabrer M, Serra G, Gogorza MS, Pereg V. Hypocalcemia due to 22q11. 2 deletion syndrome diagnosed in adulthood. Endocrinol Diabetes Metab Case Rep 2018; 2018: 17–0140.
Cao Z, Yu R, Dun K, Burke J, Caplin N, Greenaway T. 22q11.2 deletion presenting with severe hypocalcaemia, seizure and basal ganglia calcification in an adult man. Intern Med J 2011; 41: 63–66.
Chen X, Yang L, Li J, Tan H. Hypoparathyroidism and late‐onset hypogonadism in an adult male with familial 22q11. 2 deletion syndrome: a case report with 3‐year follow‐up and review of the literature. BMC Endocr Disord 2022; 22: 1–11.
Furuya K, Sasaki Y, Takeuchi T, Urita Y. Characteristics of 22q 11.2 deletion syndrome undiagnosed until adulthood: an example suggesting the importance of psychiatric manifestations. BMJ Case Rep 2015; 2015: bcr2014208903.
Hoshino Y, Machida M, Shimano S‐i, Taya T. An adult case of chromosome 22q11. 2 deletion syndrome associated with a high‐positioned right aortic arch. Intern Med 2017; 56: 865–872.
Isgandarova K, Molatta S, Sommer P. Late diagnosed DiGeorge syndrome in a 44‐year‐old female: a rare cause for recurrent syncopes in adulthood – a case report. Eur Heart J Case Rep 2021; 5: ytab166.
Johnston PC, Donnelly DK, Morrison PJ, Hunter SJ. DiGeorge syndrome presenting as late onset hypocalcaemia in adulthood. Ulster Med J 2008; 77: 201–202.
Kar P, Ogoe B, Poole R, Meeking D. Di‐George syndrome presenting with hypocalcaemia in adulthood: two case reports and a review. J Clin Pathol 2005; 58: 655–657.
Korpaisarn S, Trachoo O, Sriphrapradang C. Chromosome 22q11. 2 deletion syndrome presenting as adult onset hypoparathyroidism: clues to diagnosis from dysmorphic facial features. Case Rep Endocrinol 2013; 2013: 802793.
Maalouf NM, Sakhaee K, Odvina CV. A case of chromosome 22q11 deletion syndrome diagnosed in a 32‐year‐old man with hypoparathyroidism. J Clin Endocrinol Metab 2004; 89: 4817–4820.
McCusker L, Jenkins N, Hancock J. Hypocalcaemia in a patient with congenital heart disease. J R Soc Med 2007; 100: 51–53.
Mokrysheva N, Mirnaya S, Eremkina A, Dobreva E, Bibik E, eds. Various Clinical Features of Digeorge Syndrome. Endocrine Abstracts 2019; 63: P102.
Moreira F, Brás A, Lopes JR, Januário C. Parkinson's disease with hypocalcaemia: adult presentation of 22q11. 2 deletion syndrome. BMJ Case Rep 2018; 2018: bcr2017223751.
Novoselsky C, Codish S, Manor E, Khait K, Sukenik S. DiGeorge syndrome presenting as hypocalcemia in an adult woman. Isr Med Assoc J 2004; 6: 562–563.
Nucera C, Vaccaro M, Moleti M, Priolo C, Tortorella G, Angioni A et al. Antiphospholipid antibodies syndrome associated with hyperhomocysteinemia related to MTHFR gene C677T and A1298C heterozygous mutations in a young man with idiopathic hypoparathyroidism (DiGeorge syndrome). J Clin Endocrinol Metab 2006; 91: 2021–2026.
Okazaki T, Hifumi T, Ibata T, Manabe A, Hamaya H, Yoshimoto T et al. Recurrent convulsions, hypocalcemia, and hypoparathyroidism related to delayed diagnosis of 22q11. 2 deletion syndrome in a middle‐aged man. Acute Med Surg 2016; 3: 397–399.
Özkale M, Erol İ. 22q11.2 microdeletion in two adolescent patients who presented with convulsion. Turk Arch Pediatr 2014; 49: 70–73.
Passen E, Frigerio M, Valaperta R, Costa E, Ambrosi B, Corbetta S. Adult onset hypoparathyroidism in a patient with psychiatric illness: a 71 years delayed diagnosis of DiGeorge syndrome. J Endocrinol Invest 2010; 33: 852–853.
Sasaki Y, Obara H, Shimabukuro A. A 32‐year‐old woman diagnosed with 22q11. 2 deletion syndrome and complicated by hypothyroidism. Gen Med 2014; 15: 72–75.
Shah A, Sinnott B. Newly diagnosed hypoparathyroidism as the initial presentation of DiGeorge syndrome in a 26‐year‐old man. AACE Clin Case Rep 2022; 8: 181–182.
Shea Y‐F, Lee C‐h, Harinder G et al. Delayed diagnosis of 22q11. 2 deletion syndrome in an adult Chinese lady. Chin Med J (Engl) 2012; 125: 2945–2947.
Tonelli AR, Kosuri K, Wei S, Chick D. Seizures as the first manifestation of chromosome 22q11. 2 deletion syndrome in a 40‐year old man: a case report. J Med Case Reports 2007; 1: 1–5.
Tsai P‐L, Lian L‐M, Chen W‐H. Hypocalcemic seizure mistaken for idiopathic epilepsy in two cases of DiGeorge syndrome (chromosome 22q11 deletion syndrome). Acta Neurol Taiwan 2009; 18: 272–275.
van den Berge K, Diderich K, Poddighe P, Berghout A. Symptomatic hypoparathyroidism based on a 22q11 deletion first diagnosed in a 43‐year‐old woman. Neth J Med 2009; 67: 102–104.
van den Bosch MA, Wittebol S, van Dijk H, Kramer MH. Hypocalcemic tetany as an early sign of DiGeorge syndrome in an adult woman. Am J Med 2002; 112: 161–162.
van der Meijs ME, Schweitzer DH, Boom H. Palatoschisis, schizophrenia and hypocalcaemia: phenotypic expression of 22q11. 2 deletion syndrome (DiGeorge syndrome) in an adult. Eur J Case Rep Intern Med 2021; 8: 002411.
Yang H‐C, Lin S‐H, Wu Y‐Y, Sung C‐C. Hypoparathyroidism concomitant with macrothrombocytopenia in an elderly woman with 22q11. 2 deletion syndrome. Platelets 2018; 29: 733–736.
Zammit A, Grech Marguerat D, Psaila J, Attard A. DiGeorge syndrome presenting as hypocalcaemia‐induced seizures in adulthood. Case Rep Med 2013; 2013: 1–4.
Chow L, Waye M, Garcia‐Barcelo M, Chiu H, Fung K, Lee C. Velo‐cardio‐facial syndrome, schizophrenia and deletion at chromosome 22q11. J Intellect Disabil Res 1998; 42: 184–188.
Friedman N, Rienstein S, Yeshayahu Y, Gothelf D, Somech R. Post‐childhood presentation and diagnosis of DiGeorge syndrome. Clin Pediatr (Phila) 2016; 55: 368–373.
Hacıhamdioğlu B, Berberoğlu M, Şıklar Z, Doğu F, Bilir P, Erdeve ŞS et al. Case report: two patients with partial DiGeorge syndrome presenting with attention disorder and learning difficulties. J Clin Res Pediatr Endocrinol 2011; 3: 95–97.
Kook SD, An SK, Kim KR, Kim WJ, Lee E, Namkoong K. Psychotic features as the first manifestation of 22q11. 2 deletion syndrome. Psychiatry Investig 2010; 7: 72–74.
Kraus C, Vanicek T, Weidenauer A, Khanaqa T, Stamenkovic M, Lanzenberger R et al. DiGeorge syndrome: relevance of psychiatric symptoms in undiagnosed adult patients. Cent Eur J Med 2018; 130: 283–287.
Praharaj SK, Sarkar S, Sinha VK. Velocardiofacial syndrome presenting as chronic mania. Psychiatry Clin Neurosci 2010; 64: 666.
Rizvi S, Khan AM, Saeed H, Aribara AM, Carrington A, Griffiths A et al. Schizophrenia in DiGeorge syndrome: a unique case report. Cureus 2018; 10: e3142.
Sieberer M, Haltenhof H, Haubitz B, Pabst B, Miller K, Garlipp P. Basal ganglia calcification and psychosis in 22q11. 2 deletion syndrome. Eur Psychiatry 2005; 20: 567–569.
Tastuzawa Y, Sekinaka K, Suda T, Matsumoto H, Otabe H, Nonoyama S et al. An interictal schizophrenia‐like psychosis in an adult patient with 22q11. 2 deletion syndrome. Epilepsy Behav Case Rep 2015; 3: 36–38.
Verhoeven W, Tuinier S, Engelen J, Hollanders‐Crombach H, Curfs L. Velo‐cardio‐facial syndrome: clinical report of a 70‐year‐old woman. Am J Med Genet 2002; 111: 409–411.
Zalewska E, Obołończyk Ł, Gnacińska‐Szymańska ME, Sworczak K. Coexistence of DiGeorge syndrome with Fahr syndrome, mosaic turner syndrome and psychiatric symptoms – a case report. Psychiatr Pol 2021; 55: 397–404.
Comont T, Treiner E, Giraud J, Fusaro M, Picard C. A complex infectious, inflammatory, and autoimmune phenotype reveals 22q11. 2 deletion syndrome in an adult. J Allergy Clin Immunol 2021; 41: 1946–1949.
DePiero AD, Lourie EM, Berman BW, Robin NH, Zinn AB, Hostoffer RW. Recurrent immune cytopenias in two patients with DiGeorge/velocardiofacial syndrome. J Pediatr 1997; 131: 484–486.
King C. Undiagnosed DiGeorge syndrome presenting in middle age with an aortic root aneurysm and chronic dissection. BMJ Case Rep 2015; 2015: bcr2015210697.
Campbell JM, Knutsen AP, Becker BA. A 39‐year‐old father is diagnosed in adulthood as having partial DiGeorge anomaly with a combined T‐ and B‐cell immunodeficiency after diagnosis of the condition in his daughter. Ann Allergy Asthma Immunol 2008; 100: 620–621.
Lee S‐K, Lee E‐J, Kwun K‐H, Kim T‐J, Lee S‐K. Delayed diagnosis of chromosome 22q11. 2 deletion syndrome due to late‐onset generalized epilepsy. J Clin Neurol 2020; 16: 154–156.
Oki M, Hori S‐i, Asayama S, Wate R, Kaneko S, Kusaka H. Early‐onset Parkinson's disease associated with chromosome 22q11. 2 deletion syndrome. Intern Med 2016; 55: 303–305.
Pollard R, Hannan M, Tanabe J, Berman BD. Early‐onset Parkinson disease leading to diagnosis of 22q11. 2 deletion syndrome. Parkinsonism Relat Disord 2016; 25: 110–111.
Liu Y, Zhu H, Zhang X, Hu T, Zhang Z, Wang J et al. Infertility in a man with oligoasthenozoospermia associated with mosaic chromosome 22q11 deletion. Mol Genet Genomic Med 2018; 6: 1249–1254.
Özcan A, Şahin Y. DiGeorge syndrome associated with azoospermia: first case in the literature. Turk J Urol 2017; 43: 390–392.
Altshuler E, Saidi A, Budd J. DiGeorge syndrome: consider the diagnosis. BMJ Case Rep 2022; 15: e245164.
Beddow R, Smith M, Kidd A, Corbett R, Hunter A. Diagnosis of distal 22q11. 2 deletion syndrome in a patient with a teratoid/rhabdoid tumour. Eur J Med Genet 2011; 54: 295–298.
Ichinose Y, Kurita T, Satake A, Natori T, Shindo K, Takiyama Y. A patient with ossification of the yellow ligament and ventriculomegaly with 22q11. 2 deletion syndrome undiagnosed until adulthood. Heliyon 2020; 6: e05600.
Bilezikian JP, Khan A, Potts JT Jr, Brandi ML, Clarke BL, Shoback D et al. Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target‐organ involvement, treatment, and challenges for future research. J Bone Miner Res 2011; 26: 2317–2337.
Goswami R, Sharma R, Sreenivas V, Gupta N, Ganapathy A, Das S. Prevalence and progression of basal ganglia calcification and its pathogenic mechanism in patients with idiopathic hypoparathyroidism. Clin Endocrinol (Oxf) 2012; 77: 200–206.
Donzuso G, Mostile G, Nicoletti A, Zappia M. Basal ganglia calcifications (Fahr's syndrome): related conditions and clinical features. Neurol Sci 2019; 40: 2251–2263.
Khan AA, Bilezikian JP, Brandi ML, Clarke BL, Gittoes NJ, Pasieka JL et al. Evaluation and management of hypoparathyroidism summary statement and guidelines from the second international workshop. J Bone Miner Res 2020; 37: 2568–2585.
Schneider M, Debbané M, Bassett AS, Chow EWC, Fung WLA, van den Bree MBM et al. Psychiatric disorders from childhood to adulthood in 22q11. 2 deletion syndrome: results from the international consortium on brain and behavior in 22q11.2 deletion syndrome. Am J Psychiatry 2014; 171: 627–639.
Baker K, Vorstman JA. Is there a core neuropsychiatric phenotype in 22q11. 2 deletion syndrome? Curr Opin Neurol 2012; 25: 131–137.
Swillen A, Moss E, Duijff S. Neurodevelopmental outcome in 22q11. 2 deletion syndrome and management. Am J Med Genet A 2018; 176: 2160–2166.
Duijff SN, Klaassen PW, de Veye HFS, Beemer FA, Sinnema G, Vorstman JA. Cognitive development in children with 22q11. 2 deletion syndrome. Br J Psychiatry 2012; 200: 462–468.
Green T, Gothelf D, Glaser B, Debbane M, Frisch A, Kotler M et al. Psychiatric disorders and intellectual functioning throughout development in velocardiofacial (22q11. 2 deletion) syndrome. J Am Acad Child Adolesc Psychiatry 2009; 48: 1060–1068.
Butcher NJ, Kiehl T‐R, Hazrati L‐N, Chow EWC, Rogaeva E, Lang AE et al. Association between early‐onset Parkinson disease and 22q11. 2 deletion syndrome: identification of a novel genetic form of Parkinson disease and its clinical implications. JAMA Neurol 2013; 70: 1359–1366.
Mok KY, Sheerin U, Simón‐Sánchez J, Salaka A, Chester L, Escott‐Price V et al. Deletions at 22q11. 2 in idiopathic Parkinson's disease: a combined analysis of genome‐wide association data. Lancet Neurol 2016; 15: 585–596.
Smetanova J, Milota T, Rataj M, Bloomfield M, Sediva A, Klocperk A. Accelerated maturation, exhaustion, and senescence of T cells in 22q11. 2 deletion syndrome. J Clin Immunol 2022; 42: 274–285.
Deshpande DR, Demirdag YY, Marsh RA, Sullivan KE, Orange JS, Consortium U. Relationship between severity of T cell lymphopenia and immune dysregulation in patients with DiGeorge syndrome (22q11. 2 deletions and/or related TBX1 mutations): a USIDNET study. J Allergy Clin Immunol 2021; 41: 29–37.
Zemble R, Prak EL, McDonald K, McDonald‐McGinn D, Zackai E, Sullivan K. Secondary immunologic consequences in chromosome 22q11. 2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome). Clin Immunol 2010; 136: 409–418.
Tang JK, Rabkin SW. Hypocalcemia‐induced QT interval prolongation. Cardiology 2022; 147: 191–195.
Bassett AS, Chow EW, Husted J et al. Clinical features of 78 adults with 22q11 deletion syndrome. Am J Med Genet A 2005; 138: 307–313.
Kruszka P, Addissie YA, McGinn DE et al. 22q11. 2 deletion syndrome in diverse populations. Am J Med Genet A 2017; 173: 879–888.
Lewyllie A, Roosenboom J, Indencleef K, Claes P, Swillen A, Devriendt K et al. A comprehensive craniofacial study of 22q11. 2 deletion syndrome. J Dent Res 2017; 96: 1386–1391.
Devriendt K, Fryns J‐P, Mortier G, Van Thienen M, Keymolen K. The annual incidence of DiGeorge/velocardiofacial syndrome. J Med Genet 1998; 35: 789–790.
Nakada Y, Terui K, Kageyama K, Tsushima Y, Murakami H, Soma Y et al. An adult case of 22q11. 2 deletion syndrome diagnosed in a 36‐year‐old woman with hypocalcemia caused by hypoparathyroidism and Hashimoto's thyroiditis. Intern Med 2013; 52: 1365–1368.